Aura Biosciences (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 20,401 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 20,401 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total value of $103,229.06. Following the sale, the insider directly owned 232,284 shares in the company, valued at $1,175,357.04. This represents a 8.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $5.25 on Wednesday. The business has a fifty day moving average price of $5.60 and a two-hundred day moving average price of $5.97. The stock has a market capitalization of $333.38 million, a PE ratio of -2.71 and a beta of 0.46. Aura Biosciences, Inc. has a fifty-two week low of $4.34 and a fifty-two week high of $8.03.

Analysts Set New Price Targets

Several equities analysts have commented on AURA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 29th. Evercore started coverage on shares of Aura Biosciences in a research report on Tuesday, November 25th. They set an “outperform” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AURA. Tower Research Capital LLC TRC lifted its holdings in shares of Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after acquiring an additional 2,104 shares during the last quarter. ProShare Advisors LLC acquired a new position in Aura Biosciences during the 4th quarter worth approximately $59,000. Water Island Capital LLC bought a new position in Aura Biosciences in the 3rd quarter valued at approximately $64,000. 49 Wealth Management LLC acquired a new stake in Aura Biosciences in the third quarter valued at approximately $66,000. Finally, Invesco Ltd. bought a new stake in shares of Aura Biosciences during the second quarter worth $76,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences News Summary

Here are the key news stories impacting Aura Biosciences this week:

• Neutral Sentiment: Short-interest entries on Feb. 16–17 report a “large/significant increase” but show 0 shares and NaN changes, indicating likely data/reporting errors rather than genuine new short activity. This is an uncertain/neutral factor.
• Negative Sentiment: Insider sale — Los Pinos Elisabet De (insider) sold 47,648 shares at an average ~$5.06 (reducing her stake ~10.42%). SEC filing: Los Pinos Elisabet De sale
• Negative Sentiment: Insider sale — Amy Elazzouzi (SVP) sold 8,549 shares at an average ~$5.06 (reducing her stake ~10.17%). SEC filing: Amy Elazzouzi sale
• Negative Sentiment: Insider sale — Janet Jill Hopkins sold 20,401 shares at an average ~$5.06 (reducing her stake ~8.07%). SEC filing: Janet Jill Hopkins sale
• Negative Sentiment: Insider sale — Mark Plavsic (CTO) sold 15,890 shares at an average ~$5.05 (reducing his stake ~8.05%). SEC filing: Mark Plavsic sale
• Negative Sentiment: Insider sale — Conor Kilroy sold 12,079 shares at an average ~$5.05 (reducing his stake ~6.74%). SEC filing: Conor Kilroy sale

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.